Table 2.
Multivariate analysis of PCDH17 expression for overall survival and disease-free survival in the TCGA cohort
| Variables | Overall survival | Disease-free survival | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Full cohort | (n = 173) | (n = 171) | ||
| PCDH17 a | 2.04 (1.37–3.04) | < 0.001 | 1.89 (1.19–2.98) | 0.007 |
| Ageb | 2.90 (1.94–4.34) | < 0.0001 | 1.52 (0.96–2.43) | 0.08 |
| WBC countc | – | – | 2.14 (1.36–3.39) | 0.001 |
| Cytogenetic riskd | 1.84 (1.28–2.65) | 0.001 | 1.39 (0.95–2.04) | 0.09 |
| TP53 e | 2.76 (1.37–5.55) | 0.004 | 2.64 (0.93–7.47) | 0.07 |
| DNMT3A e | 1.61 (1.05–2.48) | 0.03 | 1.41 (0.85–2.33) | 0.18 |
| RUNX1 e | 1.75 (0.94–3.26) | 0.08 | – | – |
| CN-AML | (n = 80) | (n = 80) | ||
|---|---|---|---|---|
| PCDH17 a | 2.02 (1.13–3.62) | 0.02 | 1.79 (0.93–3.44) | 0.08 |
| Ageb | 2.38 (1.35–4.19) | 0.003 | 2.19 (1.10–4.36) | 0.03 |
| WBC countc | 1.42 (0.81–2.48) | 0.22 | 1.65 (0.89–3.04) | 0.11 |
| FLT3-ITDf | – | – | 1.34 (0.60–2.99) | 0.47 |
| TP53 e | – | – | 4.09 (0.46–36.02) | 0.20 |
| DNMT3A e | 1.99 (1.13–3.52) | 0.02 | 2.15 (1.15–4.03) | 0.02 |
| IDH1 e | 0.61 (0.21–1.78) | 0.36 | 0.68 (0.22–2.08) | 0.49 |
Hazard Ratio > 1 or Hazard Ratio < 1 indicate a higher or lower risk. Only variables with a univariable P ≤ 0.20 were included in the multivariable models. See Additional file 1: Table S3 for a full list of variables evaluated in univariable analysis
TCGA The Cancer Genome Atlas, CI confidence interval, WBC white blood cells, CN-AML cytogenetically normal AML, ITD internal tandem duplication
aLow vs high expression
b > 60 vs ≤ 60 years
c ≥ 30 vs < 30 × 109/L
dAdverse vs intermediate vs favorable
eMutated vs wild type
fPresent vs absent